Boston Scientific Corporation
BSX
$103.06
-$0.235-0.23%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.35% | 17.60% | 15.65% | 13.64% | 12.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.35% | 17.60% | 15.65% | 13.64% | 12.74% |
| Cost of Revenue | 21.47% | 20.47% | 16.82% | 15.31% | 11.55% |
| Gross Profit | 18.40% | 16.32% | 15.13% | 12.90% | 13.28% |
| SG&A Expenses | 16.45% | 15.30% | 15.62% | 11.66% | 14.20% |
| Depreciation & Amortization | 2.62% | 3.38% | 2.44% | 3.56% | 3.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.46% | 16.25% | 14.43% | 11.92% | 11.65% |
| Operating Income | 28.48% | 24.22% | 21.64% | 22.32% | 18.32% |
| Income Before Tax | 15.30% | 14.95% | 17.43% | 41.89% | 50.35% |
| Income Tax Expenses | 20.42% | 10.94% | -36.01% | -46.74% | -28.60% |
| Earnings from Continuing Operations | 14.21% | 15.94% | 45.57% | 100.11% | 96.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 300.00% | 600.00% | -- | -- | -- |
| Net Income | 14.54% | 16.31% | 45.89% | 100.55% | 96.78% |
| EBIT | 28.48% | 24.22% | 21.64% | 22.32% | 18.32% |
| EBITDA | 21.23% | 18.22% | 16.00% | 16.64% | 13.99% |
| EPS Basic | 14.20% | 16.72% | 48.46% | 108.22% | 104.44% |
| Normalized Basic EPS | 32.13% | 28.95% | 23.34% | 25.34% | 18.78% |
| EPS Diluted | 15.06% | 16.87% | 47.85% | 105.95% | 102.64% |
| Normalized Diluted EPS | 31.81% | 28.65% | 23.10% | 25.14% | 18.63% |
| Average Basic Shares Outstanding | 0.86% | 1.27% | 1.69% | 2.13% | 2.00% |
| Average Diluted Shares Outstanding | 1.11% | 1.53% | 1.90% | 2.30% | 2.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -1.00% | -1.00% | -0.87% |